Minaris Regenerative Medicine, LLC

https://www.minaris.com

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. The wholly-owned regional subsidiary companies and entities within Minaris Regenerative Medicine, encompassing a global footprint of over 200,000 square feet and employee base of over 500, have adopted the same name: > North America: Hitachi Chemical Advanced Therapeutics Solutions, LLC is renamed Minaris Regenerative Medicine, LLC, effective today > Europe: apceth Biopharma GmbH is renamed Minaris Regenerative Medicine GmbH, effective today > Asia: Hitachi Chemical’s Yokohama regenerative medicine facility adopted the use of Minaris Regenerative Medicine as its brand name Hitachi Chemical, the parent company of Minaris Regenerative Medicine, will be renamed Showa Denko Materials, Co., Ltd. on October 1, 2020 as previously announced. *

	Start	2020-09-23 renamed
	Group	Resonac (Group)
	Predecessor	Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS)
	Industry	cell therapy
	Industry 2	contract manufacturing (biologicals)
	Person	Furuishi, Kazuchika (Showa Denko 202009 Head Minaris Regenerative Medicine business + CEO Minaris LLC

	Region	United States (USA)_oo
	Country	United States (USA)
	City	n. a.
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Minaris Regnerative Medicine GmbH. (9/23/20). "Press Release: Hitachi Chemical’s Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine". Allendale, NJ, Munich & Yokohama.

		Record changed: 2023-07-10